Response to familial hypercholesterolemia: An under-recognized but significant concern in cardiology practice Foody JM et al. Clin Cardiol. doi: 10.1002/clc.22223.

Clinical Cardiology

Volumn 37, Issue 6, 2014, Pages 386-387

  Bell, Damon A ^a,b   Watts, Gerald F ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Department of Clinical Biochemistry Lipid Disorders Clinic Cardiometabolic Service   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENERAL PRACTITIONER; HUMAN; INHERITANCE; LETTER; LIPID ANALYSIS; PREVALENCE; RECOGNITION; SCREENING TEST; BLOOD; CARDIOLOGY; HYPERLIPOPROTEINEMIA TYPE II;

ANTILIPEMIC AGENT; CHOLESTEROL;

CARDIOLOGY; CHOLESTEROL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS;

EID: 84902548331     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22257     Document Type: Letter

References (12)

1. Foody JM,. Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice [published online ahead of print November 5, 2013]. Clin Cardiol. doi: 10.1002/clc.22223.
2. Bell DA, Garton-Smith J, Vickery A, et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia [published online ahead of print August 29, 2013]. Heart Lung Circ. doi: 10.1016/j.hlc.2013.08.005.
3. Jervis L, Hanson M, Bell D, et al. An audit of pharmacists' knowledge of familial hypercholesterolaemia: implications for community healthcare. Aust Pharm. July 2013: 73-75.
4. Robinson JG, Goldberg AC,; National Lipid Association Expert Panel on Familial H. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5 (3 suppl): S18-S29.
5. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011; 12: 221-231.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34: 3478-3490.
7. Hopkins PN, Toth PP, Ballantyne CM, et al; National Lipid Association Expert Panel on Familial H. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5 (3 suppl): S9-S17.
8. Watts GF, Juniper A, van Bockxmeer F, et al. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. Int J Evid Based Healthc. 2012; 10: 211-221.
9. Daniels SR, Gidding SS, de Ferranti SD,; National Lipid Association Expert Panel on Familial H. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5 (3 suppl):S30-S37.
10. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011; 218: 272-280.
11. Bell DA, Hooper AJ, Bender R, et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann Clin Biochem. 2012; 49 (pt 6): 534-537.
12. Bell DA, Bender R, Hooper AJ, et al. Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clin Chim Acta. 2013; 422: 21-25.